Opko Health, Inc. (NASDAQ:OPK) Given Consensus Rating of “Hold” by Brokerages

Shares of Opko Health, Inc. (NASDAQ:OPK) have been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $15.83.

A number of research analysts recently commented on the company. Jefferies Group LLC reissued a “hold” rating and issued a $8.00 price target on shares of Opko Health in a report on Monday, June 12th. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a report on Friday, July 21st. Barrington Research lifted their price objective on Opko Health to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 18th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $19.50 price objective on shares of Opko Health in a research note on Tuesday, June 6th. Finally, BidaskClub raised Opko Health from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd.

COPYRIGHT VIOLATION NOTICE: This report was first published by [[site]] and is the property of of [[site]]. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at [[permalink]].

Shares of Opko Health (OPK) opened at 6.09 on Friday. The company’s market capitalization is $3.41 billion. Opko Health has a 1-year low of $5.99 and a 1-year high of $12.15. The company’s 50 day moving average is $6.33 and its 200-day moving average is $7.22.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The firm had revenue of $314.20 million for the quarter, compared to analysts’ expectations of $322.64 million. During the same period in the previous year, the firm earned $0.02 EPS. The business’s quarterly revenue was down 12.0% on a year-over-year basis. On average, equities research analysts forecast that Opko Health will post ($0.19) EPS for the current year.

In related news, CEO Phillip Md Et Al Frost acquired 9,200 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was purchased at an average cost of $6.60 per share, for a total transaction of $60,720.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $20,255,076.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John A. Paganelli acquired 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were bought at an average price of $6.17 per share, with a total value of $30,850.00. Following the completion of the purchase, the director now directly owns 350,340 shares in the company, valued at $2,161,597.80. The disclosure for this purchase can be found here. Insiders acquired a total of 1,552,400 shares of company stock worth $9,871,527 in the last ninety days. 40.19% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. Janney Capital Management LLC raised its position in shares of Opko Health by 37.2% in the first quarter. Janney Capital Management LLC now owns 19,730 shares of the biotechnology company’s stock worth $157,000 after buying an additional 5,348 shares in the last quarter. IFC Holdings Incorporated FL raised its stake in Opko Health by 15.9% in the first quarter. IFC Holdings Incorporated FL now owns 15,339 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 2,100 shares during the period. RK Asset Management LLC raised its stake in Opko Health by 0.4% in the first quarter. RK Asset Management LLC now owns 887,719 shares of the biotechnology company’s stock valued at $7,102,000 after buying an additional 3,300 shares during the period. Capstone Asset Management Co. raised its stake in Opko Health by 8.6% in the first quarter. Capstone Asset Management Co. now owns 17,646 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 1,400 shares during the period. Finally, Bank of Montreal Can raised its stake in Opko Health by 1.4% in the first quarter. Bank of Montreal Can now owns 1,044,576 shares of the biotechnology company’s stock valued at $8,357,000 after buying an additional 14,559 shares during the period. 22.94% of the stock is currently owned by institutional investors and hedge funds.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.